Colin R. Green

Colin R. Green

Company: University of Auckland/OcuNexus Therapeutics, Inc. & InflammX Therapeutics, Inc.

Job title: Professor/Chief Scientist


Inflammasome Targeting in Ocular & Neurodegenerative Disease 9:30 am

Connexin hemichannel regulation prevents ATP induced activation of the inflammasome Connexin hemichannel regulation on its own is sufficient to shut down the inflammasome in ocular and neurodegenerative disease InflammX Therapeutics clinical trial plans and progressRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.